NEDD4L and Miyoshi myopathy: We found that the NEDD4L E3 ligase mediated the sensitivity of MM cells to only proteasomal inhibitors (including bortezomib, carfilzomib and ixazomib, Supplementary Fig. 2C, D) and not other drugs, such as lenalidomide, doxorubicin and melphalan (Supplementary Fig. 2E, F), suggesting that NEDD4L expression could be used to identify patients most likely to benefit from PI-based therapy.